Answer
The median half-life of ustekinumab in patients with Crohn’s disease is approximately 3 weeks.
Sources for this answer
- STELARA 130 mg concentrate for solution for infusionJanssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §5.2 Pharmacokinetic properties · Version 25Document updated
Sources checked